UCB SA (VIE:UCB)
Austria flag Austria · Delayed Price · Currency is EUR
183.45
-7.80 (-4.08%)
At close: Aug 1, 2025, 5:30 PM CET

UCB SA Company Description

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome.

It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis.

Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; UCB0222 for the treatment of Parkinson’s disease; and UCB9741 and UCB1381 for atopic dermatitis.

Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

UCB SA
CountryBelgium
Founded1925
IndustryBiological Products, Except Diagnostic Substances
Employees9,378
CEOJean-Christophe Tellier

Contact Details

Address:
Allée de la Recherche, 60
Brussels, 1070
Belgium
Phone32 2 559 99 99
Websiteucb.com

Stock Details

Ticker SymbolUCB
ExchangeVienna Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyEUR
SIC Code2836

Key Executives

NamePosition
Jean-Christophe TellierChief Executive Officer
Sandrine DufourChief Financial Officer
Antje WitteHead of Investor Relations